Overview

Phase Ib Study of SC Milatuzumab in SLE

Status:
Completed

Trial end date:
2009-06-01

Target enrollment:

Participant gender:

Summary

Milatuzumab will be given subcutaneously at different dose levels once (depending on the dose level) for 4 weeks to determine if milatuzumab helps to control lupus (SLE).

Phase:

Phase 1

Details

Lead Sponsor:

Gilead Sciences
Immunomedics, Inc.

Collaborator:

United States Department of Defense